Ovarian cancer drugs market size was valued at $4.2 billion in 2024 and is projected to reach $7.2 billion in 2035, growing at a CAGR of 6.9% during the forecast period (2025-2035). This growth is driven by growing incidence rates of ovarian cancer, early detection through enhanced imaging and genomic technologies, and increasing use of PARP inhibitors and immunotherapy-based therapies.
North America dominated the market share for the ovarian cancer treatment drugs market with robust clinical research infrastructure, well-established cancer screening guidelines, and availability of new therapies.
The rising rate of incidence and prevalence of ovarian cancer globally has increased the need for effective diagnostic techniques. For instance, in 2025, the American Cancer Society estimates that about 20,890 new ovarian cancer cases will be diagnosed in women in the U.S., and about 12,730 women will die due to the disease.
